October 15, 2020 10:40 AM EDTUpdated 02:18 PM

News briefing: Otsuka’s $886M cancer drug is now a 3-time loser in PhIII; Keytruda approved for classical Hodgkin lymphoma

Two years after Otsuka unveiled a flop in their first Phase III trial of guadecitabine as a frontline treatment, they’re

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

News brief­ing: Ot­su­ka’s $886M can­cer drug is now a 3-time los­er in PhI­II; Keytru­da ap­proved for clas­si­cal Hodgkin lym­phoma